How the NAP Peptide (Davunetide) Protects Brain Cells by Targeting the Cytoskeleton

This is a perspective/review article summarizing 15 years of the author's research program on ADNP and its peptide fragment NAP (davunetide). It integrates findings from protein interaction studies, cytoskeletal binding assays, and chromatin remodeling research to present a unified model of ADNP/NAP neuroprotection.

This paper connects several major threads in neuroscience: autism genetics (ADNP mutations), neurodegeneration (tau pathology and Alzheimer's), and peptide drug development (davunetide). By identifying the precise molecular target of NAP/davunetide — the EB-binding SIP domain on the cytoskeleton — it moves the field from knowing the peptide works to understanding exactly how it works. This mechanistic clarity is essential for improving peptide drug design and for understanding why ADNP mutations cause neurodevelopmental disorders.

NAP/davunetide has been one of the most studied neuroprotective peptides, tested in clinical trials for conditions from Alzheimer's to schizophrenia to progressive supranuclear palsy. While clinical results have been mixed, this mechanistic work represents a key advance in understanding exactly what the peptide targets. The connection between ADNP mutations (causing autism), cytoskeletal dysfunction, and tauopathy creates a unified framework that links neurodevelopmental and neurodegenerative diseases through a single protein — and a single peptide drug candidate.

This is a review from the laboratory that discovered ADNP, which may introduce perspective bias. The precise molecular target identification is based on in vitro protein interaction data and may not fully capture the complexity of NAP's effects in living brain tissue. Davunetide's clinical trial for progressive supranuclear palsy (a tauopathy) failed to meet its primary endpoints, raising questions about translating these mechanistic findings to clinical benefit.